Applications of high-throughput DNA sequencing to benign hematology

Blood

Volumn 122, Issue 22, 2013, Pages 3575-3582

  Sankaran, Vijay G ^a,b   Gallagher, Patrick G ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BENIGN NEOPLASM; CANCER GROWTH; CELL LINEAGE; DNA SEQUENCE; ERYTHROCYTE; GENETIC TRAIT; GENOTYPE PHENOTYPE CORRELATION; HEMATOLOGY; HIGH THROUGHPUT SEQUENCING; LEUKOCYTE; MEDICAL ETHICS; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; WHOLE GENOME SEQUENCING; BLOOD; ETHICS; EXOME; GENETIC ASSOCIATION; GENETICS; HEMATOLOGIC DISEASES; HUMAN; PROCEDURES;

EXOME; GENETIC ASSOCIATION STUDIES; GENOME-WIDE ASSOCIATION STUDY; HEMATOLOGIC DISEASES; HEMATOLOGY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS;

EID: 84892507301     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-460337     Document Type: Review

References (87)

1. Wintrobe MM. Blood, Pure and Eloquent: A Story of Discovery, of People, and of Ideas. New York, NY: McGraw-Hill; 1980.
2. Pauling L, Itano HA, et al. Sickle cell anemia a molecular disease. Science. 1949;110(2865): 543-548.
3. Perutz MF, Rossmann MG, Cullis AF, Muirhead H, Will G, North AC. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by x-ray analysis. Nature. 1960;185(4711):416-422.
4. Ingram VM. A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. 1956; 178(4537):792-794.
5. Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010;24(6):1005-1020.
6. Royer-Pokora B, Kunkel LM, Monaco AP, et al. Cloning the gene for an inherited human disorder-chronic granulomatous disease-on the basis of its chromosomal location. Nature. 1986;322(6074):32-38.
7. Shendure J, Lieberman Aiden E. The expanding scope of DNA sequencing. Nat Biotechnol. 2012; 30(11):1084-1094.
8. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013;5(189): 189sr184.
9. Kiezun A, Garimella K, Do R, et al. Exome sequencing and the genetic basis of complex traits. Nat Genet. 2012;44(6):623-630.
10. Senapathy P, Bhasi A, Mattox J, Dhandapany PS, Sadayappan S. Targeted genome-wide enrichment of functional regions. PLoS ONE. 2010;5(6):e11138.
11. Stitziel NO, Kiezun A, Sunyaev S. Computational and statistical approaches to analyzing variants identified by exome sequencing. Genome Biol. 2011;12(9):227.
12. Biesecker LG, Burke W, Kohane I, Plon SE, Zimmern R. Next-generation sequencing in the clinic: are we ready? Nat Rev Genet. 2012;13(11): 818-824.
13. Rehm HL. Disease-targeted sequencing: a cornerstone in the clinic. Nat Rev Genet. 2013; 14(4):295-300.
14. Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012;122(11):3799-3806.
15. Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature. 2013;493(7432):356-363.
16. Knies K, Schuster B, Ameziane N, et al. Genotyping of fanconi anemia patients by whole exome sequencing: advantages and challenges. PLoS ONE. 2012;7(12):e52648.
17. Schuster B, Knies K, Stoepker C, et al. Whole exome sequencing reveals uncommon mutations in the recently identified Fanconi anemia gene SLX4/FANCP. Hum Mutat. 2013;34(1):93-96.
18. Shamseldin HE, Elfaki M, Alkuraya FS. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet. 2012; 49(3):184-186.
19. Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet. 2002;10(11):773-781.
20. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003;348(1):33-40.
21. Lee S. The value of DNA analysis for antigens of the Kell and Kx blood group systems. Transfusion. 2007;47(suppl 1):32S-39S.
22. Walker RH, Schulz VP, Tikhonova IR, et al. Genetic diagnosis of neuroacanthocytosis disorders using exome sequencing. Mov Disord. 2012;27(4):539-543.
23. Cullinane AR, Vilboux T, O'Brien K, et al; NISC Comparative Sequencing Program. Homozygosity mapping and whole-exome sequencing to detect SLC45A2 and G6PC3 mutations in a single patient with oculocutaneous albinism and neutropenia. J Invest Dermatol. 2011;131(10):2017-2025.
24. Fernandez BA, Green JS, Bursey F, et al; FORGE Canada Consortium. Adult siblings with homozygous G6PC3 mutations expand our understanding of the severe congenital neutropenia type 4 (SCN4) phenotype. BMC Med Genet. 2012;13:111.
25. Weiss MJ, Mason PJ, Bessler M. What's in a name? J Clin Invest. 2012;122(7):2346-2349.
26. Boria I, Garelli E, Gazda HT, et al. The ribosomal basis of Diamond-Blackfan anemia: mutation and database update. Hum Mutat. 2010;31(12): 1269-1279.
27. Gerrard G, Valgañón M, Foong HE, et al. Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia. Br J Haematol. 2013;162(4):530-536.
28. Sankaran VG, Ghazvinian R, Do R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012; 122(7):2439-2443.
29. Campbell AE, Wilkinson-White L, Mackay JP, Matthews JM, Blobel GA. Analysis of disease-causing GATA1 mutations in murine gene complementation systems. Blood. 2013; 121(26):5218-5227.
30. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008; 40(5):569-571.
31. Khuong-Quang DA, Schwartzentruber J, Westerman M, et al. Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy. Pediatrics. 2013; 131(2):e620-e625.
32. Rabbani B, Mahdieh N, Hosomichi K, Nakaoka H, Inoue I. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet. 2012;57(10):621-632.
33. Gallagher PG. Disorders of red cell volume regulation. Curr Opin Hematol. 2013;20(3): 201-207.
34. Carella M, Stewart G, Ajetunmobi JF, et al. Genomewide search for dehydrated hereditary stomatocytosis (hereditary xerocytosis): mapping of locus to chromosome 16 (16q23-qter). Am J Hum Genet. 1998;63(3):810-816.
35. Zarychanski R, Schulz VP, Houston BL, et al. Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. Blood. 2012;120(9):1908-1915.
36. Albuisson J, Murthy SE, Bandell M, et al. Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels. Nat Commun. 2013;4:1884.
37. Andolfo I, Alper SL, De Franceschi L, et al. Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1. Blood. 2013;121(19):3925-3935.
38. Coste B, Xiao B, Santos JS, et al. Piezo proteins are pore-forming subunits of mechanically activated channels. Nature. 2012;483(7388): 176-181.
39. van der Harst P, Zhang W, Mateo Leach I, et al. Seventy-five genetic loci influencing the human red blood cell. Nature. 2012;492(7429):369-375.
40. Stepensky P, Saada A, Cowan M, et al. The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy. Blood. 2013; 121(25):5078-5087.
41. Vilboux T, Lev A, Malicdan MC, et al. A congenital neutrophil defect syndrome associated with mutations in VPS45. N Engl J Med. 2013;369(1): 54-65.
42. Walne AJ, Dokal A, Plagnol V, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica. 2012; 97(4):524-528.
43. Kirwan M, Walne AJ, Plagnol V, et al. Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet. 2012;90(5): 888-892.
44. Walne AJ, Vulliamy T, Kirwan M, Plagnol V, Dokal I. Constitutional mutations in RTEL1 cause severe dyskeratosis congenita. Am J Hum Genet. 2013; 92(3):448-453.
45. Ballew BJ, Yeager M, Jacobs K, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Hum Genet. 2013;132(4):473-480.
46. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653-2655.
47. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10): 1012-1017.
48. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011; 43(10):929-931.
49. Kazenwadel J, Secker GA, Liu YJ, et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood. 2012; 119(5):1283-1291.
50. Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood. 2013;121(19):3830-3837.
51. Pasquet M, Bellanné-Chantelot C, Tavitian S, et al. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood. 2013;121(5):822-829.
52. Bhatnagar P, Purvis S, Barron-Casella E, et al. Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. J Hum Genet. 2011;56(4):316-323.
53. Cole JW, Stine OC, Liu X, et al. Rare variants in ischemic stroke: an exome pilot study. PLoS ONE. 2012;7(4):e35591.
54. Dworkis DA, Klings ES, Solovieff N, et al. Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. Am J Hematol. 2011;86(2):220-223.
55. Milton JN, Sebastiani P, Solovieff N, et al. A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLoS ONE. 2012;7(4):e34741.
56. Sebastiani P, Solovieff N, Hartley SW, et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol. 2010;85(1): 29-35.
57. Nelson MR, Wegmann D, Ehm MG, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012;337(6090):100-104.
58. Tennessen JA, Bigham AW, O'Connor TD, et al; Broad GO; Seattle GO; NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012; 337(6090):64-69.
59. Coppola G, Chinnathambi S, Lee JJ, et al; Alzheimer's Disease Genetics Consortium. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet. 2012; 21(15):3500-3512.
60. Ji W, Foo JN, O'Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008; 40(5):592-599.
61. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science. 2004;305(5685):869-872.
62. Romeo S, Pennacchio LA, Fu Y, et al. Populationbased resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007;39(4):513-516.
63. Peters LL, Lambert AJ, Zhang W, Churchill GA, Brugnara C, Platt OS. Quantitative trait loci for baseline erythroid traits. Mamm Genome. 2006; 17(4):298-309.
64. Mahaney MC, Brugnara C, Lease LR, Platt OS. Genetic influences on peripheral blood cell counts: a study in baboons. Blood. 2005;106(4): 1210-1214.
65. Strzalkowska A, Unrug-Bielawska K, Bluszcz A, et al. Quantitative trait loci analysis for peripheral blood parameters in a (BALB/cW x C57BL/6J-Mpl (hlb219)/J) F(2) mice. Exp Anim. 2011;60(4): 405-416.
66. Soranzo N, Spector TD, Mangino M, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009; 41(11):1182-1190.
67. Ferreira MA, Hottenga JJ, Warrington NM, et al. Sequence variants in three loci influence monocyte counts and erythrocyte volume. Am J Hum Genet. 2009;85(5):745-749.
68. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010;42(12):1049-1051.
69. Auer PL, Johnsen JM, Johnson AD, et al. Imputation of exome sequence variants into population-based samples and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome Sequencing Project. Am J Hum Genet. 2012;91(5):794-808.
70. Cheung YH, Wang G, Leal SM, Wang S. A fast and noise-resilient approach to detect rare-variant associations with deep sequencing data for complex disorders. Genet Epidemiol. 2012;36(7): 675-685.
71. Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011;13(3):255-262.
72. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148(6):1293-1307.
73. Lyon GJ, Jiang T, Van Wijk R, et al. Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications. Discov Med. 2011;12(62):41-55.
74. Cassa CA, Savage SK, Taylor PL, Green RC, McGuire AL, Mandl KD. Disclosing pathogenic genetic variants to research participants: quantifying an emerging ethical responsibility. Genome Res. 2012;22(3):421-428.
75. Tabor HK, Berkman BE, Hull SC, Bamshad MJ. Genomics really gets personal: how exome and whole genome sequencing challenge the ethical framework of human genetics research. Am J Med Genet A. 2011;155A(12):2916-2924.
76. Solomon BD, Hadley DW, Pineda-Alvarez DE, et al. Incidental medical information in whole-exome sequencing. Pediatrics. 2012; 129(6):e1605-e1611.
77. ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet Med. 2012;14(8):759-761.
78. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565-574.
79. Allyse M, Michie M. Not-so-incidental findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing. Trends Biotechnol. 2013;31(8):439-441.
80. Wolf SM, Annas GJ, Elias S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. Science. 2013;340(6136):1049-1050.
81. McGuire AL, Joffe S, Koenig BA, et al. Pointcounterpoint. Ethics and genomic incidental findings. Science. 2013;340(6136):1047-1048.
82. Jacob HJ, Abrams K, Bick DP, et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med. 2013;5(194):194cm5.
83. Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;362(13):1181-1191.
84. Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet. 2013;45(3): 299-303.
85. Piton A, Redin C, Mandel JL. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. Am J Hum Genet. 2013;pii:S0002-9297(13)00282-6.
86. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease [published online ahead of print July 3, 2013]. Hum Genet.
87. Xue Y, Chen Y, Ayub Q, et al; 1000 Genomes Project Consortium. Deleterious- and diseaseallele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet. 2012;91(6):1022-1032.